Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1995-06-07
2000-01-11
Scheiner, Laurie
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
530300, 530324, 530325, 530326, 4241841, 4241861, A61K 39165
Patent
active
060132639
ABSTRACT:
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
REFERENCES:
Wild et al., 1992, "A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition", Proc. Natl. Acad. Sci. USA 89:10537-10541.
Mitsuya et al., 1991, "Targeted therapy of human immunodeficiency virus-related disease", FASEB J. 5:2369-2381.
Hammarskjold and Rekosh, 1989, "The molecular biology of the human immunodeficiency virus", Biochem. Biophys. Acta 989:269-280.
Guyader et al., 1987, "Genome organization and transactivation of the human immunodeficiency virus type 2", Nature 326:662-229.
Claval et al., 1986, "Isolation of a new human retrovirus from west african patients with AIDS", Science 233:343-348.
Maddon et al., 1986, "The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain", Cell 47:333-348.
McDougal et al., 1986, "Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule", Science 231:382-385.
Barin et al., 1985, "Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients", Science 228:1094-1096.
Dalgleish et al., 1984, "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus", Nature 312:763-767.
Gallo et al., 1984 "Frequent detection and isolation of cytopathic retroviruses (HTLV-III from patients with AIDS and at risk for AIDS", Science 224:500-503.
Klatzmann et al., 1984, "T-lumphocyte T4 molecule behaves as the receptor for human retrovirus LAV", Nature 312:767-768.
Teich et al., 1984, Pathogenesis of lentivirus, in "RNA Tumor Viruses", Weiss et al., eds., CSH-Press, pp. 949-956.
Barre-Sinoussi et al., 1983, "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)", Science 220:868-870.
Chen, 1994, "Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41", J. Virology 68:2002-2010.
Carr and Kim, 1993, "Aspring loaded mechanism for the conformational change of influenza hemagglutinin", Cell 73:823-832.
Songyang et al., 1992, "SH2 domains recognize specific phosphopeptide sequences", Cell 72:767-778.
Lam et al., 1991, "The new type of synthetic peptide library for identifying ligand-binding activity", Nature 354:82-84.
Lupas et al., "Predicting coiled coils from protein sequences", Science 252:1162-1165.
Xu et al., 1991, "Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies", J. Virology 65:4832-4838.
Chambers et al., 1990, "Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins", J. Gen. Virology 71:3075-3080.
Malim et al., 1988, "Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes", Nature 355:181-183.
Suzuki et al., 1995, "Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogenic and Syngeneic Tumors", J of Experimental Medicine 182:477-486.
Wild et al., 1994, "Propensity for a Leucine Zipper-Like Doman of Human Immunodeficiency Virus Type 1 gp41 to Form Oligomers Correlates With a Role in Virus-Induced Fusion Rather Than Assembly of the Glycoprotein Complex", Proc. Natl. Acad. Sci. USA 91:12676-80.
Bousse et al., 1994, "Regions on the Hemagglutinin-Neuraminidase Proteins of Human Parainfluenza Virus Type-1 and Sendai Virus Important for Membrane Fusion", Virology 204:506-514.
Wang et al., 1993, "Ion Channel Activity of Influenza A Virus M2 Protein: Characterization of the Amantidine Block", J of Virology 57:5585-94.
Lazinski et al., 1993, "Relating Structure to Function in the Hepatitis Delta Virus Antigen", J of Virology 67:2572-80.
White, J.M., 1992, "Membrane Fusion", Science 258:917-924.
Daar et al., 1990, "High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates", Proc. Natl. Acad. Sci. USA 87:6574-6579.
Erickson et al., 1990, "Design, Activity, and 2.8 .ANG. Crystal Structure of a C.sub.2 Symmetric Inhibitor Complexed to HIV-1 Protease", Science 249:527-533.
Smith et al., 1987, "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen", Science 238:1704-1707.
Collins et al., 1984, "Nucleotide Sequence of the Gene Encoding the Fusion (F) Glycoprotein of Human Respiratory Syncytial Virus", Proc. Natl. Acad. Sci. USA 81:7683-87.
Barney Shawn O'Lin
Lambert Dennis Michael
Petteway Stephen Robert
Parkin Jeffrey S.
Scheiner Laurie
Trimeris, Inc.
LandOfFree
Measles virus peptides with antifusogenic and antiviral activiti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Measles virus peptides with antifusogenic and antiviral activiti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Measles virus peptides with antifusogenic and antiviral activiti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459936